Cystic Fibrosis News

With the recent addition of two pediatric pulmonologists, the Cystic Fibrosis Center at Children’s Hospital Los Angeles continues to advance research on this disease, especially for children from diverse racial and ethnic backgrounds.

In addition to suffering with cystic fibrosis, patients with this condition often contract lung infections that are difficult to treat; however, an upcoming study may reveal a way to lower infection prevalence.

Patients with cystic fibrosis frequently experience bacterial infections, but a zinc transport protein may be able to lower infection incidence, according to findings published in Proceedings of the National Academy of Sciences.

Patients with cystic fibrosis had reduced lung function if they had at least one 12-month or longer gap in receiving care, according to findings published in Annals of the American Thoracic Society.

In patients with cystic fibrosis, a new genetic technology could permanently fix the CF transmembrane conductance regulator gene in hundreds of disease-causing CF mutations, according to a press release from the Cystic Fibrosis Foundation.

In patients aged 6 to 21 years with cystic fibrosis receiving pulmonary exacerbation treatment, changing antibiotics was not clinically beneficial, according to results published in Annals of the American Thoracic Society.

Patients with cystic fibrosis had improved chronic rhinosinusitis outcomes after 1 year of elexacaftor/tezacaftor/ivacaftor therapy, according to results published in JAMA Otolaryngology-Head & Neck Surgery.

Elexacaftor/tezacaftor/ivacaftor appeared safe and well tolerated among kids aged 12 years and older with cystic fibrosis and either F508del/minimal function or F508del/F508del genotypes for up to 144 weeks, according to study results.

Yearly paranasal sinus MRI imaging allowed physicians to track chronic rhinosinusitis development in children with cystic fibrosis, according to results published in Annals of the American Thoracic Society.

The FDA granted orphan drug designation to ARCT-032 as a treatment for patients with cystic fibrosis, according to a press release from Arcturus Therapeutics.